InMed Pharmaceuticals (INM) CEO Eric Adams details 250-option expiry

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. reported an insider derivatives transaction involving its President & CEO and Director, Eric A. Adams, dated 12/15/2025. The filing shows an employee stock option labeled "Employee Stock Option (Expiration)" tied to 250 derivative securities related to the company's common shares.

The option carried a U.S. dollar exercise price of $1,397.97 per the form, calculated from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00. Following this reported transaction, Adams directly beneficially owns 14,050 derivative securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ADAMS ERIC A

(Last) (First) (Middle)

C/O INMED PHARMACEUTICALS INC.

1445-885 WEST GEORGIA ST.

(Street)

VANCOUVER A1 V6C3E8

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Expiration)	$1,397.97(1)	12/15/2025		H			250	12/16/2020	12/15/2025	Common shares	250	$0.00	14,050	D

Explanation of Responses:

1. Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00

	/s/ Eric A Adams	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InMed Pharmaceuticals (INM) report in this Form 4?

The Form 4 reports an employee stock option (Expiration) transaction dated 12/15/2025 involving 250 derivative securities tied to InMed Pharmaceuticals common shares.

Who is the reporting person in the InMed Pharmaceuticals (INM) Form 4?

The reporting person is Eric A. Adams, who is both a Director and the President & CEO of InMed Pharmaceuticals Inc.

How many options and underlying shares are involved in Eric Adams' Form 4 for INM?

The Form 4 shows 250 derivative securities described as an employee stock option, with an underlying amount of 250 common shares of InMed Pharmaceuticals.

What is the exercise price of the employee stock option reported for INM?

The employee stock option has an exercise price of $1,397.97, which is stated as converted from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00.

How many derivative securities does Eric Adams own after the reported INM transaction?

After the reported transaction, Eric A. Adams beneficially owns 14,050 derivative securities, held with direct ownership.

What were the key dates for the employee stock option in the INM Form 4?

The Form 4 lists the option as first exercisable on 12/16/2020 with an expiration date of 12/15/2025, and the transaction date is also 12/15/2025.